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Studies were undertaken to further elucidate the mechanism(s) by which bradykinin-dependent phosphoino- 
sitide metabolism takes place in neuroblastoma x glioma hybrid NG108-15 cells [(1984) J. Biol. Chem. 
259. 10201-10207] using [3H]inositol-labelled cells. Bradykinin produced net increases in the level of [3H]ino- 
sitol phosphates, especially of [3H]inositol trisphosphate which is formed transiently and most rapidly. The 
results indicate that bradykinin activates a phosphodiesterase to break down phosphatidylinositol 4,5-bis- 
phosphate, generating two recently recognized intracellular messengers, 1,2-diacylglycerol and inositol 
trisphosphate. 
Neuroblastoma x glioma Bradykinin 
1. INTRODUCTION 
In many cell systems, Ca2+-mobilising hormones 
and neurotransmitters can cause a rapid break- 
down of PIP2 through activation of a phospho- 
diesterase [ 11. It has become increasingly apparent 
that the products of the phosphodiesteratic hydro- 
lysis of PIP2 may serve as intermediates in the 
transmembrane signalling [I]: 1,2-diacylglycerol 
activates protein kinase C [2] and (1,4,5)IP3 acts as 
a mobiliser of intracellular Ca2+ [3-91. These two 
putative second messengers are thought to syner- 
gistically activate the cells to carry out their 
physiological functions [IO, 1 I]. 
A previous report from our laboratory 1121 
showed that bradykinin induces a rapid loss of 
radioactivity from PIP2, independently of a rise in 
intracellular Ca2+ concentration, in 32Pi-labelled 
neuroblastoma x glioma hybrid NG108-I5 cells. 
Abbreviations: IPx, inositol trisphosphate; (1,4,5)IP3, 
inositol 1,4,5trisphosphate; IP2, inositol b&phosphate; 
IP, inositol monophosphate; PIP2, phosphatidylinositol 
4,5-bisphosphate 
Inositol trisphosphate Phosphodiesterase 
However, because of the multiple pathways in 
which phosphoinositides are metabolized [13], 
studies using “P labelling were unable to lead us to 
the conclusion as to the enzyme(s) which causes the 
loss of PIP& 
The aim here, therefore, is to establish the 
metabolic pathway by which PIP2 is hydrolyzed in 
the bradykinin-stimulated NG108-15 cells. To 
achieve this, we have studied the effects of brady- 
kinin on the accumulation of [3H]inositol phos- 
phates in the hybrid cells prelabelled with [3H]in- 
ositol. The results show that bradykinin rapidly 
enhances the level IP3 which is subsequently 
degraded to IP;? and further to IP. Here, we can 
conclude that the bradykinin-induced PIP2 break- 
down in NGlOS-15 cells is due to activation of a 
phosphodiesterase. 
2. MATERIALS AND METHODS 
2.1. Cell culture 
NG108-15 cells were cultured essentially as 
described previously [ 14,151. 
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2.2. Studies with [3H]inositol-labelled cells 
NG108-15 cells which had been grown for 6 days 
in monolayer cultures were released from culture 
dishes with a rubber policeman. The harvested 
cells were washed once with Tris-buffered saline 
(TBS) consisting of 20 mM Tris-HCl (pH 7.4), 150 
mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM 
MgS04 and 25 mM glucose. The washed cells 
(3 x lo7 cells) were then incubated in 20 ml of the 
same buffer supplemented with 120 ,&i of [3H]in- 
ositol (Amersham) at 37°C. After 2.5 h, the 
medium was replaced with 20 ml of fresh TBS with 
no inositol and further incubated for 1 h. The 
labelled cells were washed two times with TBS and 
finally suspended in TBS containing 10 mM LiCl 
at a final concentration of 4 x lo6 cells/ml. The in- 
clusion of LiCl was to inhibit IP phosphatase 
[16,17]. Aliquots (0.25 ml) of the cell suspension 
were transferred to siliconized tubes and after 5 
min preincubation at 37”C, bradykinin (Protein 
Research Foundation, Osaka) solution (0.05 ml) 
was added to give a final concentration of 1 x 10e5 
M. For control incubations, the same volume of 
vehicle (TBS) alone was always added. At desig- 
nated times, the reaction was terminated by the ad- 
dition of 0.1 ml of 10% (w/v) perchloric acid [ 181. 
The acid-soluble extract was neutralized with 0.15 
ml of 1.53 M KOH-75 mM Hepes, and perchloric 
acid was precipitated on ice and removed by a brief 
centrifugation. The aqueous extract was then 
diluted to 5 ml with distilled water and was applied 
to a column (0.6x4.0 cm) of AG-1 x2, 200-400 
mesh (Bio-Rad), which had been converted to for- 
mate form. After free inositol and glycerophos- 
phoinositol were eluted with 16 ml of S mM 
sodium tetraborate/60 mM ammonium formate, 
total inositol phosphates were eluted with 12 ml of 
1 .O M ammonium formate/O. 1 M formic acid, or 
individual inositol phosphates were eluted sequen- 
tially using 16 ml of 0.2 M ammonium formate/O. 1 
M formic acid for IP, 20 ml of 0.4 M ammonium 
formate/O.l M formic acid for IPz, and 12 ml of 
1 .O M ammonium formate/O. 1 M formic acid for 
IP3 as described by Berridge et al. [19]. Radioac- 
tivity in each fraction was counted with a Beckman 
liquid scintillation counter, LS 7500 model, in the 
gel phase using 60% (v/v) Aquasol (New England 
Nuclear) [20]. Usually, 4-ml samples of the eluates 
were collected and mixed with Aquasol. In the case 
of 1.0 M ammonium formate/O.l M formic acid 
404 
eluates, however, 2-ml samples were diluted to 4 
ml with distilled water and then Aquasol was add- 
ed so that the gel phase can be formed. 
2.3. Expression of data 
Data in table 1 and fig.1 are expressed as the 
mean +SE of 4 samples from two experiments, 
each performed in duplicate. 
3. RESULTS AND DISCUSSION 
The effect of bradykinin on the level of [‘HIin- 
ositol phosphates is presented in table 1. Brady- 
kinin caused an increase in [3H]inositol phosphates 
to 3.1-fold of control at 5 min. This finding in- 
dicates that bradykinin is capable of activating 
phosphodiesterase(s) which degrades phosphoino- 
sitides. 
In order to determine the primary substrate of 
the bradykinin-stimulated phosphoinositide break- 
down, the time course of the effect of bradykinin 
on the release of individual inositol phosphates 
was examined. As shown in fig. 1, the addition of 
bradykinin to [3H]inositol-labelled cells induced a 
rapid occurrence of IP3, which reached a peak 
(3.4-fold increase of control) at 10 s. There was a 
subsequent accumulation of IPz and it was max- 
imally enhanced by 3.5-fold at 30 s. The levels of 
these two inositol phosphates then gradually 
declined and returned to near-control levels by 5 
min. The increase of IP level, in contrast, was 
small at the onset but became greater with an in- 
cubation time up to 5 min. This time sequential 
generation of inositol phosphates in the order of 
IP3, IP2 and IP, taken together with the previous 
observation [121 that bradykinin causes a preferen- 
tial loss of 32P-PIP~ from prelabelled cells, in- 
Table 1 
Bradykinin-stimulated increase in the content of total in- 
ositol phosphates 
[3H]Inositol phosphates 
(dpm/ lo6 cells) 
Control Bradykinin 
1249 + 265 3918 f 318 
[3H]Inositol-labelled NGlOS-15 cells were incubated at 
37°C for 5 min with or without 1 x lo-’ M bradykinin. 
Total inositol phosphates were separated as described in 
section 2 
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Fig.1. Time course of the effect of bradykinin on the 
production of individual inositol phosphates in 
[‘Hlinositol-labelled NGl08-15 cells. [3H]Inositol- 
labelled NGlOI-15 cells were incubated at 37°C for 5 
min with or without 1 x lo-’ M bradykinin. The in- 
dividual inositol phosphates were separated as described 
in section 2. Data are expressed as percentages of their 
respective controls. Control values at zero time for 
[3H]IP3, [3H]IP~ and [‘HJIP (dpm/106 cells) were 
156 + 47, 369 + 74 and 660 * 48, respectively. 
dicates that the primary substrate of the brady- 
kinin-activated phosphodiesterase is PIP2. The in- 
crease in the content of IP2 and IP, therefore, is 
most likely to be the result of the sequential 
degradation of IP3 to IP2 and IP2 to IP by their 
respective phosphatases [19,21,22]. However, the 
possibility of phosphatidylinositol 4-phosphate 
breakdown to yield IPz cannot be excluded. 
The results obtained here demonstrate that 
bradykinin-receptor interaction in NG108-15 cells 
can produce two putative second messengers, IPs 
and 1,2-diacylglycerol by a stimulated phospho- 
diesteratic hydrolysis of PIP2. Diacylglycerol is 
thought to play a pivotal role in cell activation by 
phosphorylating target protein(s) through protein 
kinase C [l 11, and IPs by releasing Ca2+ from in- 
ternal store(s) [l]. We have shown previously that 
bradykinin provokes a depolarization preceded by 
a transient hyperpolarization in NG 108- 15 cells, 
ultimately leading to the release of acetylcholine 
[12]. In this context, it is of great interest to note 
the observations which indicate that (1,4,5)IPs in- 
duces a marked depolarization in the ventral 
photoreceptors of Limuhs, usually provoked by 
light [23,24]. The precise role of these two putative 
second messengers in the physiological functions 
of NG108-15 cells remain to be clarified. Studies 
using Quin-2 on Ca2+ mobilisation in the brady- 
kinin-stimulated NG108-15 cells are currently 
under investigation in our laboratory. 
Bradykinin has emerged as a potential neuro- 
transmitter in the central nervous system [25], and 
a recent work by Perry and Snyder [26] substan- 
tiated the presence of bradykinin in mammalian 
brain, especially in a higher quantity in hypo- 
thalamus. Whether the action of bradykinin ob- 
served in the neuron-like cell line NG108-15 
reflects the events occurring in the central nervous 
system awaits further exploration. 
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